National Institute of Allergy and Infectious Disease (NIAID): Clinical Trials Database PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download National Institute of Allergy and Infectious Disease (NIAID): Clinical Trials Database PDF full book. Access full book title National Institute of Allergy and Infectious Disease (NIAID): Clinical Trials Database by . Download full books in PDF and EPUB format.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Presents the Clinical Trials Database of the National Institute of Allergy and Infectious Diseases (NIAID). Includes entries for studies of experimental treatments and vaccines for infectious, immunologic, and allergic diseases conducted or supported by NIAID. Allows searches to be performed for extramural or intramural trials.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Presents the Clinical Trials Database of the National Institute of Allergy and Infectious Diseases (NIAID). Includes entries for studies of experimental treatments and vaccines for infectious, immunologic, and allergic diseases conducted or supported by NIAID. Allows searches to be performed for extramural or intramural trials.
Author: Vassil St. Georgiev
Publisher: Springer Science & Business Media
ISBN: 1603272976
Category : Medical
Languages : en
Pages : 769
Get Book Here
Book Description
National Institute of Allergy and Infectious Diseases, NIH: Volume 2: Impact on Global Health covers the scientific aspects of the entire portfolio of NIAID, including microbiology and infectious disease, HIV/AIDS, and immunology and vaccines. All major diseases and the relevant immunology and vaccine development are described in detail. In addition, all major NIAID programs, initiatives, and clinical trials are discussed and illustrate the global involvement of NIAID in biomedical research and its impact on public health worldwide. By providing this information, the global scientific community will be able to access and benefit from these programs and initiatives.
Author: Vassil St. Georgiev
Publisher: Humana Press
ISBN: 9781607614814
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
National Institute of Allergy and Infectious Diseases, NIH: Volume 2: Impact on Global Health covers the scientific aspects of the entire portfolio of NIAID, including microbiology and infectious disease, HIV/AIDS, and immunology and vaccines. All major diseases and the relevant immunology and vaccine development are described in detail. In addition, all major NIAID programs, initiatives, and clinical trials are discussed and illustrate the global involvement of NIAID in biomedical research and its impact on public health worldwide. By providing this information, the global scientific community will be able to access and benefit from these programs and initiatives.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309316324
Category : Medical
Languages : en
Pages : 236
Get Book Here
Book Description
Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309174414
Category : Medical
Languages : en
Pages : 112
Get Book Here
Book Description
Infectious diseases remain a leading cause of prolonged illness, premature mortality, and soaring health costs. In the United States in 1995, infectious diseases were the third leading cause of death, right behind heart disease and cancer. Mortality is mounting over time, owing to HIV/AIDS, pneumonia, and septicemia, with drug resistance playing an ever-increasing role in each of these disease categories. This book, a report from a Forum on Emerging Infections workshop, focuses on product areas where returns from the market might be perceived as being too small or too complicated by other factors to compete in industrial portfolios with other demands for investment. Vaccines are quintessential examples of such products. The lessons learned fall into four areas, including what makes intersectoral collaboration a reality, the notion of a product life cycle, the implications of divergent sectoral mandates and concepts of risk, and the roles of advocacy and public education. The summary contains an examination of the Children's Vaccine Initiative and other models, an industry perspective on the emerging infections agenda, and legal and regulatory issues.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Clinical trials of substances being tested for use against AIDS, HIV infection, and AIDS-related opportunistic diseases is the subject of this database. Each record covers a single trial, and provides information such as title and purpose of the trial, diseases studied, patient eligibility criteria, contact persons, agents being tested, and trial locations. Information about the trials sponsored by the National Institutes of Health is supplied by the National Institute of Allergy and Infectious Diseases (NIAID), while information about privately sponsored trials is provided by the Food and Drug Administration (FDA). AIDSTRIALS is a part of the AIDS Clinical Trials Information Service (ACTIS), which is a Public Health Service project sponsored by the FDA, the NIAID, the NLM, and the Centers for Disease Control.
Author: Nicola Fabris
Publisher: Springer Science & Business Media
ISBN: 1468445472
Category : Medical
Languages : en
Pages : 473
Get Book Here
Book Description
Immunoregulation is one of the areas which has witnessed the most explosive advances of immunology during the past decade. It is in this area that the current view of the immune system has arisen and developed. There is indeed little doubt that immune reactions are primarily determined by messages which are genera ted within the immune system and passed among different types of immunologie cells. This cell communication not only determines the type, intensity and duration of the response after perturbation of the immune system by exogenous antigens, but it is also essential for preventing autoimmune reactions and their clinical conse quences. In order to assure aperfect balance within the enormous com plexity of the immune system, it is not surprising that multiple self-regulatory mechanisms are organized at different levels, such as antibody feedback, idiotypic-anti-idiotypic responses, suppres sor and helper T cells, lymphokine signals and genetic require ments. A nu mb er of observations in recent years have, however, demonstrated that consistent contributions to the immunological homeostasis are given also by signals generated outside of the immune system, namely,in the central and autonomous nervous system as weIl as in the endocrine apparatus. Furthermore, the interactions between the immune system and the other body homestatic mechanisms seem to be bidirectional: if immunological cells may be targets of neuroendocrinological factors, immunological products seem in turn to contribute to the neuro endocrine homeostasis.
Author: Peter Perlmann
Publisher: Karger Medical and Scientific Publishers
ISBN: 3805573766
Category : Medical
Languages : en
Pages : 422
Get Book Here
Book Description
Despite extensive efforts to control it, malaria is still one of the most devastating infectious diseases worldwide. This book, now in its second edition, provides a broad and up-to-date overview of the rapidly expanding field of malaria immunology and its importance in the control of this disease. The first section deals with the malaria parasite and its interactions with both the vertebrate host and the mosquitoes which transmit the disease. In the second part, the mechanisms of immunity and their regulation by environmental and genetic factors are discussed. Finally, this volume contains several chapters on malaria vaccine development, describing the application of the most recent vaccine technologies as well as ongoing and planned vaccine trials. Authored by well-recognized experts, this volume not only demonstrates the rapid progress being made in the search for vaccines against malaria, but also broadens our understanding of immunity to infection in general. It is therefore highly recommended reading for all scientists and professionals in the fields of immunology, infection and vaccine development.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309176611
Category : Medical
Languages : en
Pages : 279
Get Book Here
Book Description
In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309163358
Category : Medical
Languages : en
Pages : 151
Get Book Here
Book Description
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise.
